MetaCap

Lucid Diagnostics Inc. (LUCD)

NASDAQ: LUCDHealth CareMedical/Dental InstrumentsUSD

0.3727-0.0136 (-3.52%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

LUCD stock chart

Technical analysis

Key statistics

All statistics
Market cap
$72.57M
EPS (TTM)
-$0.36
52-week range
0.303 – 1.63
Day range
0.3545 – 0.3946
Volume / Avg
2.26M / 5.15M
Beta
—

52-week range

$0.303$1.63

LUCD stock today

On Nov 20, LUCD ended the session at $0.3727, shedding $0.0136 (3.52%), versus the S&P 500's 3.70% decline. Trading was light, with 2.26M shares changing hands, about 44% of the average daily volume. At this level, LUCD sits near the bottom of its 52-week range of $0.303 to $1.63: 77.1% below the high, set on Jan 21, 2026 and 23.0% above the low.

LUCD is down 65.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 64.7%. Lucid Diagnostics has posted a net loss over the last twelve months (EPS of -$0.36), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Lucid Diagnostics

Company profile

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.

Industry
Medical/Dental Instruments
CEO
Dr. Lishan Aklog M.D.
Headquarters
New York, NY
Employees
82
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Lucid Diagnostics generated $4.7 million in revenue, up 8.3% from fiscal 2024, its 3rd consecutive year of revenue growth. Lucid Diagnostics reported a net loss of $58.0 million, compared with a loss of $45.5 million a year earlier. Gross margin was -41.7% (up from -63.3%) and operating margin -1054.8%.

Lucid Diagnostics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$4.71M$4.35M$2.43M$377.00K$500.00K
Growth+8.28%+79.00%+544.03%-24.60%—
Net income$-58.01M$-45.53M$-52.67M$-56.17M$-28.08M
EPS (diluted)—$-1.05$-1.26$-1.55$-1.51

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$4.00+973.25%

  • Strong buy 2
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $2.00High $9.50

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.07 vs $-0.07

LUCD news

All LUCD news

Lucid Diagnostics peers

Health Care sector
LUCD peer companies
CompanyPrice% ChgMarket capCompare
QTEXQTREX Quantum Ltd.1.00-10.71%$70.63Mvs LUCD
SKINSkinHealth Systems Inc. Class A11.77-3.13%$76.68Mvs LUCD
NYXHNyxoah SA0.805-7.01%$81.98Mvs LUCD
LNSRLENSAR Inc.4.46-3.88%$54.83Mvs LUCD
MBOTMicrobot Medical Inc.0.68-8.52%$45.67Mvs LUCD
APYXApyx Medical Corporation2.40+0.42%$101.10Mvs LUCD
DXRDaxor Corporation7.45-7.33%$43.49Mvs LUCD
SRTSSensus Healthcare Inc.2.26-4.24%$37.20Mvs LUCD

Indexes, lists and sector

Lucid Diagnostics stock FAQ

What is Lucid Diagnostics's stock price today?

LUCD last traded at $0.3727 as of Nov 20, 4:00 PM EST, down 3.52% on the day. Prices are delayed at least 15 minutes.

Who is Lucid Diagnostics's CEO?

Dr. Lishan Aklog M.D. is the chief executive officer of Lucid Diagnostics Inc., which has about 82 employees.

What is the LUCD 52-week high?

The 52-week high for LUCD is $1.63 and the 52-week low is $0.303. The stock is currently 77.1% below its high.

Compare LUCD